- Home
- VKTX
as 05-17-2024 4:00pm EST
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 8.1B | IPO Year: | 2015 |
| Target Price: | $103.44 | AVG Volume (30 days): | 6.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.28 - $99.41 | Next Earning Date: | 04-24-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Viking Therapeutics Inc. (VKTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ZANTE GREG | VKTX | Chief Financial Officer | May 3 '24 | Sell | $73.49 | 3,101 | $227,886.60 | 238,509 | SEC Form 4 |
| ZANTE GREG | VKTX | Chief Financial Officer | May 3 '24 | Sell | $74.44 | 45,570 | $3,392,444.98 | 192,939 | SEC Form 4 |
| ZANTE GREG | VKTX | Chief Financial Officer | May 3 '24 | Sell | $75.49 | 17,238 | $1,301,241.46 | 175,701 | SEC Form 4 |
| ZANTE GREG | VKTX | Chief Financial Officer | May 3 '24 | Sell | $76.07 | 847 | $64,434.93 | 174,854 | SEC Form 4 |
| Mancini Marianna | VKTX | Chief Operating Officer | May 1 '24 | Sell | $76.40 | 23,746 | $1,814,301.26 | 606,187 | SEC Form 4 |
| Mancini Marianna | VKTX | Chief Operating Officer | May 1 '24 | Sell | $77.49 | 26,142 | $2,025,829.85 | 580,045 | SEC Form 4 |
| Mancini Marianna | VKTX | Chief Operating Officer | May 1 '24 | Sell | $78.65 | 105,343 | $8,284,974.13 | 474,702 | SEC Form 4 |
| Mancini Marianna | VKTX | Chief Operating Officer | May 1 '24 | Sell | $79.29 | 119,946 | $9,511,058.10 | 354,756 | SEC Form 4 |
| Mancini Marianna | VKTX | Chief Operating Officer | May 1 '24 | Sell | $80.08 | 6,248 | $500,310.47 | 348,508 | SEC Form 4 |
| Lian Brian | VKTX | President & CEO | Feb 9 '24 | Sell | $29.90 | 45,000 | $1,345,500.00 | 2,139,882 | SEC Form 4 |
| Lian Brian | VKTX | President & CEO | Jan 30 '24 | Sell | $23.95 | 35,000 | $838,250.00 | 2,264,882 | SEC Form 4 |
| ZANTE GREG | VKTX | Chief Financial Officer | Jan 3 '24 | Sell | $17.90 | 15,000 | $268,500.00 | 180,730 | SEC Form 4 |
Latest Viking Therapeutics Inc. News
VKTX Breaking Stock News: Dive into VKTX Ticker-Specific Updates for Smart Investing
Motley Fool
2 days ago
3 Monster Stocks in the Making You Can Buy Right Now
Zacks
3 days ago
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Motley Fool
3 days ago
Is Viking Therapeutics Stock a Buy?
MT Newswires
3 days ago
Raymond James Upgrades Viking Therapeutics to Strong Buy From Outperform
Zacks
5 days ago
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
Motley Fool
7 days ago
How Viking Therapeutics Stock Could 30x
Motley Fool
7 days ago
Is Viking Therapeutics the Best Biotech Stock for You?
Simply Wall St.
14 days ago